Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Schizophrenia

Ibogaine for Schizophrenia

2 papers and 0 clinical trials exploring ibogaine as a treatment for schizophrenia.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
IndicationApproximately 24 million people worldwide are affected by schizophrenia.

Schizophrenia

Schizophrenia is a complex psychiatric disorder characterised by disruptions in thought processes and perception. Recent research into psychedelics has opened new avenues for understanding its neurobiology and exploring potential therapeutic mechanisms, particularly in addressing treatment-resistant symptoms.

Full Schizophrenia profile

Academic Research

2 papers
Open Accessmeta

The antiaddictive effects of ibogaine: A systematic literature review of human studies

This systematic review (2017) examined the antiaddictive effects of ibogaine (420 -; 2030mg/70kg) in humans and identified seven open-label studies that indicated that ibogaine/noribogaine significantly reduced opiate/opioid withdrawal symptoms and that many subjects remained drug-free for several days after treatment. However, these results were largely heterogeneous and the only additional clinical trial performed failed to find significant reductions in opiate/opioid withdrawal symptoms in response to noribogaine.

Published
December 19, 2016
Journal
Journal of Psychedelic Studies
Authors
Dos Santos, R. G., Bouso, J. C., Hallak, J. E.
Open Accessmeta

The psychopharmacology of hallucinogens

This review paper (1996) examines the history and epidemiology of hallucinogens (LSD, Mescaline, MDM, MDMA, Psilocybin, Ibogaine, Harmine, and DMT) with respect to their psychotic effects, hallucinogen persisting perception disorder, and therapeutic efficacy. Representative studies include 13 publications on LSD therapy to treat alcoholism (n=1409), and 16 studies on post-LSD psychoses (n=75).

Published
April 1, 1996
Journal
Neuropsychopharmacology
Authors
Abraham, H. D., Aldridge, A. M., Gogia, P.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ibogaine and Schizophrenia yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ibogaine papers Search all Schizophrenia trials Full Ibogaine profile Full Schizophrenia profile